Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Manabu, Kamiyama"'
Autor:
Koji Mita, Kouji Izumi, Akihiro Goriki, Ryo Tasaka, Tomoya Hatayama, Takashi Shima, Yuki Kato, Manabu Kamiyama, Shogo Inoue, Nobumichi Tanaka, Seiji Hoshi, Takehiko Okamura, Yuko Yoshio, Hideki Enokida, Ippei Chikazawa, Noriyasu Kawai, Kohei Hashimoto, Takashi Fukagai, Kazuyoshi Shigehara, Shizuko Takahara, Yoshifumi Kadono, Atsushi Mizokami
Publikováno v:
Cancers, Vol 16, Iss 3, p 508 (2024)
Enzalutamide (ENZ) and abiraterone plus prednisolone (ABI) can improve the survival of patients with castration-resistant prostate cancer (CRPC). However, the agent that is more effective against nonmetastatic CRPC remains unclear. To evaluate the ag
Externí odkaz:
https://doaj.org/article/0c8d0708dc23486bb9e1a381da9eb6cf
Autor:
Kouji Izumi, Takashi Shima, Koji Mita, Yuki Kato, Manabu Kamiyama, Shogo Inoue, Nobumichi Tanaka, Seiji Hoshi, Takehiko Okamura, Yuko Yoshio, Hideki Enokida, Ippei Chikazawa, Noriyasu Kawai, Kohei Hashimoto, Takashi Fukagai, Kazuyoshi Shigehara, Shizuko Takahara, Yoshifumi Kadono, Atsushi Mizokami
Publikováno v:
European Urology Open Science, Vol 41, Iss , Pp 16-23 (2022)
Background: Enzalutamide (ENZ) and abiraterone plus prednisolone (ABI) improve survival in castration-resistant prostate cancer (CRPC). However, which agent is better for patients with CRPC remains unclear. Objective: To evaluate whether ENZ or ABI i
Externí odkaz:
https://doaj.org/article/8142d33ec52941b8af422dd7c8735ba5
Publikováno v:
Urology Case Reports, Vol 44, Iss , Pp 102158- (2022)
Neuroendocrine prostate cancer (NEPC) is rare, with short overall survival, and no established standard therapy. Therefore, the management of NEPC is often challenging. We report a case of a 63-year-old male diagnosed with NEPC and treated with multi
Externí odkaz:
https://doaj.org/article/102f1d91b3fa4cafad957da91b1a20a6
Autor:
Naoki Terada, Takashi Mizowaki, Toshihiro Saito, Akira Yokomizo, Naoki Kohei, Ken‐ichi Tabata, Masaki Shiota, Atsushi Takahashi, Toru Shimazui, Takayuki Goto, Yasuhiro Hashimoto, Masato Fujii, Ryotaro Tomida, Toshihiko Sakurai, Kohei Hashimoto, Sadafumi Kawamura, Shogo Teraoka, Shinichi Sakamoto, Takahiro Kimura, Manabu Kamiyama, Shintaro Narita, Nobumichi Tanaka, Takuma Kato, Masashi Kato, Takahiro Osawa, Takahiro Kojima, Takahiro Inoue, Mikio Sugimoto, Hiroyuki Nishiyama, Toshiyuki Kamoto, Japanese Urological Oncology Group
Publikováno v:
BJUI Compass, Vol 1, Iss 5, Pp 165-173 (2020)
Abstract Objectives To evaluate the association between the use of local radiotherapy (RT) with the survival of patients with de novo metastatic prostate cancer and symptomatic local events (SLEs). Patients and methods Patients were initially diagnos
Externí odkaz:
https://doaj.org/article/d411a5e937a2439a9cd57b5b4e633f3b
Autor:
Yoshifumi Kasai, Norifumi Sawada, Takashi Yamagishi, Manabu Kamiyama, Takahiko Mitsui, Masayuki Takeda
Publikováno v:
Urology Case Reports, Vol 33, Iss , Pp 101346- (2020)
Distant urethral metastasis of the castration-resistant prostate cancer (CRPC) is very rare. In this case report, we present a 69-year-old man who was first diagnosed prostate cancer from the sessile papillary tumor in the prostatic urethra which rec
Externí odkaz:
https://doaj.org/article/2a9ffffaf5f0478285020a25a1a19b02
Autor:
Nishimoto, Koshiro, Kenichi, Nakajima, Masafumi, Oyama, Go, Kaneko, Satoru, Takahashi, Hideyasu, Matsuyama, Hiroaki, Shiina, Tomohiko, Ichikawa, Hiroyuki, Horikoshi, Katsuyoshi, Hashine, Yutaka, Sugiyama, Takeshi, Miyao, Manabu, Kamiyama, Kenichi, Harada, Akito, Ito, Atsushi, Mizokami
Publikováno v:
International Journal of Urology. 29:1477-1487
Novel androgen receptor axis-targeted agents (ARATAs) have been developed for mCRPC and improved overall survival (OS). Here, we aimed to find predictors who will receive the greatest benefits from ARATAs.We previously performed a multicenter study t
Autor:
Kouji Izumi, Atsushi Mizokami, Mikio Namiki, Shogo Inoue, Nobumichi Tanaka, Yuko Yoshio, Kei Ishibashi, Manabu Kamiyama, Noriyasu Kawai, Hideki Enokida, Takashi Shima, Shizuko Takahara
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-6 (2017)
Abstract Background Both enzalutamide and abiraterone have demonstrated improved radiographic progression-free and overall survival for castration-resistant prostate cancer (CRPC) compared with placebo controls before docetaxel treatment in phase III
Externí odkaz:
https://doaj.org/article/32dfd6c7fece45e286381a6ddefc24d9
Autor:
Taiki, Kamijima, Hiroshi, Yaegashi, Atsushi, Mizokami, Kenichi, Nakajima, Hideyasu, Matsuyama, Tomohiko, Ichikawa, Koshiro, Nishimoto, Satoru, Takahashi, Hiroaki, Shiina, Hiroyuki, Horikoshi, Katsuyoshi, Hashine, Yutaka, Sugiyama, Takeshi, Miyao, Manabu, Kamiyama, Kenichi, Harada, Akito, Ito, Hideki, Enokida
Publikováno v:
Anticancer Research. 42:3099-3108
This study aimed to evaluate the therapeutic benefit of novel androgen receptor-targeted agents (ARTAs) in castration-resistant prostate cancer (CRPC) with bone metastases in Japan.In followup to our prospective observational study (PROSTAT-BSI) from
Publikováno v:
Transplantation Proceedings. 54:671-677
Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, has been reported to be effective in treating conservative renal failure and renal anemia in patients undergoing dialysis. Nonetheless, its effect on posttransplant anemia (PTA) has
Autor:
Honglan Piao, Yuan Chi, Xiling Zhang, Zhen Zhang, Kun Gao, Manabu Niimi, Manabu Kamiyama, Jinming Zhang, Masayuki Takeda, Jian Yao
Publikováno v:
Journal of Pharmacological Sciences, Vol 132, Iss 4, Pp 224-234 (2016)
Suramin inhibits immune responses and protects cells against inflammatory cell injury. However, little is known about its mechanisms. Using an in vitro model of glomerular mesangial cell (MC) lysis induced by antibodies plus complement, we investigat
Externí odkaz:
https://doaj.org/article/af0af589ccde4e50a3b7c1edba80588c